Andere Sprachen Cosmos Health Inc.

Aktien

A3DZZN

US2214133058

COSM

Pharmazeutika

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 08.05.2026			% 5 Tage	Veränd. 1. Jan.
0,3323 ^USD	-5,06 %		-12,46 %	-33,27 %

20.04.	Cosmos Health schließt Phase 1 für Liv18 vorzeitig ab	MT
17.04.	Cosmos Health bringt Curcumin-Präparat Cur18 im zweiten Quartal auf den US-Markt	MT

Andere Sprachen

08.05.	Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed
06.05.	Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness
30.04.	Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months
21.04.	Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products
20.04.	Cosmos Health Completes Phase 1 Execution of Liv18 Ahead of Schedule
20.04.	Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio
17.04.	Cosmos Health to Launch Cur18 Curcumin Supplement in US in Q2
17.04.	Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health
16.04.	Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30%
15.04.	Cosmos Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
15.04.	Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 2026 Across All Core Segments
15.04.	Cosmos Health Inc. Auditor Raises 'Going Concern' Doubt
13.04.	Cosmos Health Gets New 60,000-Unit Sky Premium Life Order From Pharmalink
13.04.	Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units
10.04.	Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months
08.04.	Cosmos Health Continues Expansion in the United States with Q2 Launch of Liv18 - a Clinically Proven, Patented Supplement for Liver Fat Reduction
01.04.	Cosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical Markets
19.03.	Cosmos Health Says It May Use Noncore Assets to Help Fund Future Plans
19.03.	Cosmos Health says Middle East war, recent geopolitical turmoil had negligible impact on operations
19.03.	Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions
11.03.	Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000
10.03.	Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000
10.03.	Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000
24.02.	Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board
24.02.	Cosmos Health Inc. Appoints Dr. Dimitrios Iliopoulos to Advisory Board